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Stable complex coronary artery disease can be treated with coronary artery bypass grafting (CABG), percutaneous coronary intervention
(PCI), or medical therapy. Multidisciplinary decision-making has gained more emphasis over the recent years to select the most optimal treat-
ment strategy for individual patients with stable complex coronary artery disease. However, the so-called ‘Heart Team’ concept has not been
widely implemented. Yet, decision-making has shown to remain suboptimal; there is large variability in PCI-to-CABG ratios, which may pre-
dominantly be the consequence of physician-related factors that have raised concerns regarding overuse, underuse, and inappropriate selection
of revascularization. In this review, we summarize these and additional data to support the statement that a multidisciplinary Heart Team con-
sisting of at least a clinical/non-invasive cardiologist, interventional cardiologist, and cardiac surgeon, can together better analyse and interpret
the available diagnostic evidence, put into context the clinical condition of the patient as well as consider individual preference and local ex-
pertise, and through shared decision-making with the patient can arrive at a most optimal joint treatment strategy recommendation for patients
with stable complex coronary artery disease. In addition, other aspects of Heart Team decision-making are discussed: the organization and
logistics, involvement of physicians, patients, and assisting personnel, the need for validation, and its limitations.
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Introduction
There is precedence in the field of medicine that the level of care can
be improved and made more consistent with the use of multidiscip-
linary teams to recommend the most optimal treatment. An example
of this is the introduction of the tumour board in the 1960s, which
has shown to significantly improve the quality of care.1 –3 A pre-
treatment multidisciplinary discussion was associated with improved
survival as well as reduced hospital-variations in survival rates1 and
has been identified as an independent predictor of treatment
recommendations’ conformity to clinical practice guidelines.3
The area of cardiovascular diseases has seen the development of
Heart Teams early on for treatment of heart failure, pediatric and
adult cases of congenital heart disease, and more recently for
aortic and mitral valve interventions. In the context of myocardial
revascularization, multidisciplinary Heart Teams have been intro-
duced through randomized trials. While decision-making for
patients with acute indications or less complex coronary disease
may be straightforward, for patients with stable complex (e.g. left
main and/or multivessel) coronary artery disease (CAD), a Heart
Team consisting of a clinical/non-invasive cardiologist, interventional
cardiologist, and cardiac surgeon is considered optimal to best
assess the advantages and disadvantages of the various treatment
strategies. The Heart Team has recently become a class 1C recom-
mendation in European and American guidelines on myocardial
revascularization.4,5 However, while in oncology 63% of centres in
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the western countries have embraced multidisciplinary teams,6 this
approach has not yet been widely implemented for coronary indica-
tions for a myriad of reasons including the novelty of the concept,
lack of experience, lack of proven benefit, logistical issues, as well
as turf protection.7,8 Yet, clearly there is a need for improved
decision-making. A recent study suggests that non-compliance to
guidelines can result in inappropriate or underuse of revasculariza-
tion.9 In patients with an indication for coronary artery bypass graft-
ing (CABG), only 53% received such treatment, 34% underwent
percutaneous coronary intervention (PCI), 12% received medical
management, and 1% did not receive any treatment.
The purpose of the current manuscript is to explore the rationale
behind Heart Team evaluation and to advocate for wider, regular
use of Heart Teams in an orderly fashion, thereby enhancing the
value of care for patients with stable complex CAD.
Revascularization: what the Heart
Team could improve
Since CABG was demonstrated in the 1980s to be superior to
medical therapy in patients with three-vessel or left main (LM)
disease, many patients have undergone surgical revascularization.
The introduction of PCI with balloon angioplasty and subsequently
stents resulted in a consideration of both therapies as treatment
options. The different treatment strategies should ideally be con-
sidered complementary. However, evidence suggests that the
current decision-making process and treatment selection is
questionable, thereby potentially resulting in suboptimal care and
increased health care expenditures.
Variability
Owing to technical and therapeutic advancements and reduced
invasiveness, PCI has been utilized increasingly since its introduc-
tion over three decades ago. Evidence from Europe, the United
States, and Canada suggests that the PCI-to-CABG ratio has
shifted significantly towards more PCI procedures.10– 12 This is in
some degree caused by expanding indications for PCI. However,
the Organization of Economic Cooperation and Development
(OECD) reported a mean PCI-to-CABG ratio of 3.29 in 2007 in
those countries affiliated with the organization, ranging from a
low of 0.67 in Mexico to a high of 8.63 in Spain (Figure 1).13
Even within the same health care system, a large difference in
PCI-to-CABG ratios has been reported across different regions
(Figure 2).13 This wide variability in the type of revascularization
utilization might be driven by economic and reimbursement con-
siderations,14 but other factors may also be contributory. Consist-
ency and generality of recommendations might be best approached
by Heart-Team-based care.
Differences in baseline patient characteristics might explain part
of the variance in the PCI-to-CABG ratio. However, physician-
related factors dominate treatment decisions. Surgeons and cardi-
ologists significantly differ in the information they provide the
patient regarding the choice between PCI and CABG, thereby cre-
ating a bias towards a specific treatment.15 Studies have shown that
in 68% of patients who underwent PCI and 59% who underwent
Figure 1 Revascularization procedures performed in countries throughout the Western world. Data from the Organisation for Economic
Cooperation and Development (OECD) shows a great variety in the number of revascularization procedures per 100 000 inhabitants.13
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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CABG, the alternative revascularization strategy was not discussed
with the patient.16 Several overt and subconscious physician-
related factors may influence these treatment recommendations
(Table 1). To overcome these issues, the Heart Team may increase
agreement among surgeons and cardiologists with respect to the
choice of the preferred treatment.17
Decision-making
Before the decision is made to perform revascularization, assess-
ment of coronary lesions is essential. Typically, and according to
the guidelines, revascularization is indicated if there is significant
angiographic diameter stenosis (≥50–70%) with documented
ischaemia or fractional flow reserve ,0.80.4
Factors that should be taken into account prior to decision-
making are patient co-morbidities, the patient’s history, coronary
lesion complexity, and operative risk, but also the anticipated
goals of therapy and the life-expectancy or expected quality-of-life
improvement. Several risk models have been developed to esti-
mate the operative risk and long-term outcome,18– 22 which can
provide guidance for the Heart Team regarding safe and efficient
treatment recommendations. However, these risk models should
inform, not replace, clinical judgement and local operator expertise
in estimating the overall benefit–risk balance of treatment
interventions.
The STS score18 and logistic EuroSCORE19 are the most com-
monly used models to assess the patient’s operative mortality
risk. Both models include patient characteristics, co-morbidities,
previous events, and operative factors to calculate a risk of mortal-
ity. The EuroSCORE has a satisfactory inter-observer variance
(k ¼ 0.71), but still the calculation is subject to many errors,
ranging from simple encoding errors to re-calculation errors (e.g.
creatinine plasmatic level to creatinine clearance).23 It can be
expected that errors are more likely to occur in complex
models with more variables, such as the STS score or the new
EuroSCORE II.24 As a joint group the Heart Team enables an
extra check with regard to the accuracy of the scores but
cannot overcome the modest prognostic utility of scores.
Simpler risk models with a limited number of variables, such as
the ACEF score that includes only three factors,25 may also
provide satisfactory risk stratification and are likely to have fewer
errors.26
The SYNTAX score, established in 2005, was developed to
grade complexity of CAD.27 Validated in the SYNTAX trial, the
score was found to be a good predictor of adverse events in the
PCI population, however, not in CABG patients.28 Although it is
vital to acknowledge the hypothesis-generating nature of the
SYNTAX trial subgroup data, the score is a promising tool to
Figure 2 Rates of CABG and PCI in hospital referral regions within the United States. The mean rate of CABG was 5.2 per 1000 Medicare
enrollees and 11.3 for PCI. Rates are adjusted for age, sex, and race. Copied from the Dartmouth Atlas of Health Care.84 Abbreviations as
previously.
Table 1 Overt and subconscious factors that influence
whether comprehensive and well-balanced information
of revascularization strategies is provided by physicians
‘Building an empire’ leading to (inter)national recognition
Conflict of interest with industry
Knowledge of patient’s preferences
No appreciation of personal therapeutic limits
Not being up-to-date regarding PCI and/or CABG (technology,
outcomes, indications, etc.)
Opportunity to include a patient in an enroling randomized trial
Personal conflict between interventional cardiologist and/or surgeon
Physician–patient bonding
Preservation of patient–referral pathways
The physician’s centre is a centre of excellence in PCI or CABG
‘Turf protection’ (protection of patient access and salary)
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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stratify which patients can be revascularized with PCI or CABG
and numerous publications support the prognostic capacity of
the score in various patient populations.29 –33 Therefore, the
SYNTAX score is increasingly used to guide treatment decisions
and the new revascularization guidelines recommend the use of
the SYNTAX score for treatment selection.4,5 Despite the encour-
aging use of established SYNTAX Score threshold values (≤22 and
≥33), the SYNTAX Score needs to be weighted in the context of
the overall evaluation by the Heart Team which might overrule
these threshold-based decisions.34 A limitation of the SYNTAX
Score is its notable intra-observer and inter-observer variability,
which can cause inappropriate revascularization strategies
(Table 2).35– 39 The inconsistency in the SYNTAX score is in part
due to interpretations of coronary angiogram. The inaccuracy of
grading vessel stenosis on angiograms has been addressed in a
number of different studies in which a high inter-observer and
intra-observer variability of angiogram analysis was demon-
strated.40,41 However, the correlation between angiogram inter-
pretations and the ‘normal’ phantom study reference values
increased when taking the mean of three (r ¼ 0.88) and five (r ¼
0.89) physicians instead of the value of individual physicians (r ¼
0.79).41 Another study showed that by replacing individual readings
by panel readings, the appropriateness of the indication for CABG
and PCI changed from necessary or appropriate to uncertain or in-
appropriate in 33 and 10% of the cases, respectively.40 Within the
Heart Team, the members can interpret the angiograms together
and reduce errors, so that the SYNTAX score correctly represents
the patient’s lesions,36 leading to more appropriate revasculariza-
tion. Nevertheless, Heart Team treatment decisions in which the
angiographic complexity is weighted with clinical co-morbidity,
operator skills, local expertise, and patient preference are more
likely to yield improved outcomes than those based on evaluation
of angiographic complexity alone.
Interactive web-based programs can be used to provide informa-
tion on different treatment strategies with corresponding risks and
benefits, which could be helpful for both patients and physicians.
For patients, it is mandatory that the program is user-friendly and
easily interpretable so that it helps establish patient treatment
preferences, and improve patient satisfaction.42 For physicians,
such programs can be used for comprehensive risk assessment
and simulation of outcomes based on different treatment strategies.
New insights into how the individual patient can potentially be
treated with novel techniques could furthermore be provided. An
example that is frequently used in oncology is the www.
adjuvantonline.com website. To the best of our knowledge, no
program exists for cardiology and its development should be
promoted.
Inappropriate revascularization
Even though the imbalance in recommendations for therapy has
been identified as early as the 1980s, recent study showed that in-
appropriateness rates remain high (Table 3).43– 58 In a recent study
from the New York State database, of 24 545 PCI procedures per-
formed for non-acute indications of stable CAD, 14.3% were per-
formed inappropriately and in another 49.6% there was not
sufficient information and either approach could be considered
(‘uncertain’).58 Evaluation of CABG procedures showed an in-
appropriateness rate of 1.1 and 8.6% were judged uncertain.
However, it should be noted that a ‘zero tolerance’ for inappropri-
ate procedures is not expected, due to patient preferences and
factors not captured in the criteria.48,59 In addition, the recently
updated appropriateness criteria have been criticized for several
limitations,59 including the composition of the panel, the role of
pre-procedural diagnostic testing, and the fact that it does not
account for all possible scenarios of clinical care.
Substantial inter-hospital variation of treatment recommendation
may explain why the rates of inappropriateness vary significantly
between studies.48,57 Cardiologists and surgeons frequently favour
PCI or CABG, respectively.17,60,61 Appropriateness ratings can
therefore depend on specific individual choices that have been
shown to vary across geographic regions, which in turn could be a
surrogate for cultural differences.62 However, it may also be evi-
dence of particular excellence in PCI or CABG in certain centres.
Thus, evaluation of an accurate rate of inappropriate revasculariza-
tion will require adjustment for all these factors.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Observer variability in assessment of the SYNTAX score
Author, year Patients Number of
patients
Score evaluation Intra-observer
variability (k)a
Inter-observer
variability (k)a
Serruys, 200938 LM and/or 3VD 100 Two corelab technicians 0.59 for raw scores 0.45 for raw scores
0.61 for score tertiles 0.52 for score tertiles
Garg, 201035 LM and/or 3VD 100 Three interventional cardiologists 0.54 for raw scores —
Shiomi, 201139 LM 101 Two interventional cardiologists 0.69 for score tertiles 0.58 for score tertiles
Tanboga, 201137 — 76 Two interventional cardiologists 0.69 for score tertiles 0.56 for score tertiles
Ge´ne´reux, 201136 MVD 30 Three interventional cardiologists – before training — 0.33 for score tertiles
50 Three interventional cardiologists – after training 0.88, 0.64, 0.66 for
score tertiles
0.76 for score tertiles
3VD, three-vessel disease; LM, left main; MVD, multivessel disease.
aThe kappa (k) values represent the strength of agreement. This is considered to be fair between 0.21 and 0.40, moderate between 0.41 and 0.60, substantial between 0.61 and
0.80, and almost perfect between 0.81 and 1.00.86
Heart Team decision-making in CAD 2513
by guest on August 11, 2015
D
ow
nloaded from
 
Underuse of revascularization
An important limitation of the appropriateness criteria is that it can
only be applied to patients who underwent revascularization. Pref-
erably, it should be applied to all patients after a diagnostic angio-
gram or stress test, so that these criteria can also be used to
identify patients in whom revascularization is underused
(Table 4).51,63 –66 On the basis of the existing studies, in 18–34%
of patients in whom PCI was rated necessary or appropriate, no
revascularization took place. For CABG patients, this number is
25%. The incidence can vary for several patient groups; men
are more likely to undergo revascularization than women, and
whites more than blacks.63 The study by Leape et al.66 also
found a large in-hospital variance in performance of necessary
revascularization, ranging from 21 to 87% (P, 0.001). The clinical
relevance of these findings was demonstrated by significantly
higher rates of angina at 1 year [odds ratio ¼ 1.97 (1.29–3.00)]
in patients who received medical therapy while PCI would have
been appropriate.51 In a CABG patient group, this effect was
even more pronounced, with an odds ratio of 3.03 [2.08–4.42]
for angina. Furthermore, CABG patients appeared to have signifi-
cantly lower rates of death or MI compared with patients who
should have had revascularization [HR ¼ 0.25 (0.17–0.35)]. In con-
trast, there was no evidence of a difference in death or MI rates
between PCI and patients who received medical therapy [HR ¼
1.30 (0.80–2.08)].51 A recent study by Hannan et al.67
contradicted this finding. They showed that patients who should
have had PCI were more likely to experience death [14.5 vs.
10.2%, HR ¼ 1.46 (1.08–1.97)] or the composite of death or MI
[21.2 vs. 16.5%, HR ¼ 1.49 (1.16–1.93)] at 4 years when compared
with those patients who did undergo PCI. Furthermore, Filardo
et al.64 showed that underuse of any revascularization was asso-
ciated with significantly increased mortality during follow-up
[multivariate HR ¼ 3.23 (2.00–5.26)].
History of the coronary Heart
Team
Initiated in early randomized trials comparing CABG with medical
therapy for stable CAD,68,69 a Heart Team was used to select
patients eligible for randomization. Partly due to the introduction
of PCI, interventional cardiologists and cardiac surgeons were
increasingly targeting the same patient population. Randomized
trials comparing CABG and PCI followed,70,71 in which specialties
worked in close proximity to ensure accurate patient selection and
assume clinical equipoise between treatments. This provided new
insights into decision-making as performed by a Heart Team. The
EAST72 and BARI73 trials included nested registries along with the
randomized cohorts, to demonstrate if physician or patient-
treatment preferences yielded different results than patients in
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Inappropriateness of revascularization procedures
Author, year Country Inclusion Number of procedures
for stable angina
Rate of
inappropriateness, %
Rate of uncertian
appropriateness, %
PCI
Hilborne, 199352 USA 1990 519 1% 42%
Bengtson, 199446 Sweden 1990 56 5% 9%
Meijler, 199755 The Netherlands 1992 891 33.4% 36.4%
Bernstein, 199947 Sweden 1994–1995 447 36.7% 37.8%
Hemingway, 199950 UK 1995 328 43% 48%
Fitch, 200049 — — 204 15% 44%
Aguilar, 200143 Spain 1997 467 15% 23%
Yim, 200444 Korea 1997 228 8.8% 67.1%
Chan, 201148 USA 2009–2010 144 737 11.6% 38.0%
Hannan, 201258 USA 2009–2010 24 545 14.3 49.6
CABG
Winslow, 198857 USA 1979–1980, 1982 213 13 —
Gray, 199045 UK and USA 1987–1988 319 16
Bengtson, 199446 Sweden 1990 307 1 8
McGlynn, 199454 Canada and USA 1989–1990 980 15
Meijler, 199755 The Netherlands 1992 1054 4.5 13.4
Bernstein, 199947 Sweden 1994–1995 1038 8.5 13.2
Hemingway, 199950 UK 1995 323 43 38
Fitch, 200049 — — 204 19 40
O’Connor, 200856 USA 2004–2005 806 2.1 0
Hannan, 201258 USA 2009–2010 8168 1.1 8.6
‘’ indicates an approximate value that was calculated by combining the overall group and a percentage. For example, ‘34% of 287 patients had stable angina’: 0.34×287 ¼ 97.6
which would be listed here as 98. Abbreviations as previously.
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whom equipoise was assumed. Remarkably, 3-year survival of the
EAST registry patients was slightly better than randomized patients
(96.4 vs. 93.4%, P ¼ 0.044), which suggests that the selection of
treatment after discussion with a cardiologist, cardiac surgeon,
and the patient provides better outcomes in comparison to ran-
domization. Similar results were confirmed by the BARI trial,
showing improved survival of registry patients over randomized
patients at 7-year follow-up. The SYNTAX trial also included
nested registries but differed from previous trials such as EAST
and BARI registries in that inclusion was not also based on patient
preferences, but specifically focused on inclusion of patients with
assumed superiority of either PCI or CABG.28 The SYNTAX
Heart Team demonstrated the contemporary PCI/CABG distribu-
tion of patients with left main and/or three-vessel disease
(Figure 3); in 58.5% of patients both PCI and CABG was suitable,
while 6.4 and 35.0% could only undergo PCI and CABG, respective-
ly, due to co-morbid and lesion-specific factors according to the
Heart Team.34
Further evidence supporting Heart Team decision-making origi-
nated from the MASS-II trial in which patients were randomized to
PCI, CABG, or medical therapy.74 Before randomization, experi-
enced clinical/non-interventional cardiologists recorded their per-
sonal choice of treatment. Survival comparison between the
chosen and randomized treatment showed excellent outcomes
and good clinical judgement with respect to CABG and medical
therapy (Figure 4). However, survival was significantly worse in
patients randomized to PCI in whom CABG or medical therapy
would have been preferred. This speaks to the value of additional
expertise that could have improved patient selection.
At present time, both European (2010) and American (2011)
guidelines on myocardial revascularization were a joint effort of
cardiology and surgical associations.4,5 This concept recapitulates
the Heart Team, where specialists work together to optimize
treatment recommendations based on an exchange of knowledge
and experience with specific therapies.
Heart Team organization and
involvement
Organization and logistics
It has been shown that in cancer teams, up to 15% of treatment
recommendations are not implemented.75 This is most often the
case when co-morbid conditions are not discussed at the multidis-
ciplinary meeting, if patient preferences are unknown, or if further
diagnostics became available after the meeting. As emphasized by
the ‘uncertain’ classification in the appropriateness criteria, treat-
ment decisions are frequently not substantiated because there is
insufficient diagnostic data or inadequate documentation for an
evidence-based decision. Therefore, it is crucial that all necessary
patient information is available during the Heart Team meeting.
The appointment of a non-clinical coordinator would be particu-
larly helpful for gathering patient information or making sure this
is accessible electronically, ensuring the necessary attendance
and documentation of specialties that are present, and recording
treatment recommendations.
Leadership is of the utmost importance for a team to be efficient
as objectives need to be made clear, it can stimulate participation,
encourage commitment to excellence, and drive innovation.76
Active participation of all team members is a prerequisite, and
the discussion should take place in a non-autocratic setting. To
achieve a positive dynamic it is essential to have mutual respect
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Underuse of revascularization procedures
Author, year Country Inclusion Number of
patients
Revascularization not
given (%)
Outcome
PCI necessary/appropriate
Kravitz, 199565 USA 1990–1991 107 34% no PCI 3.7 vs. 5.6%
25% no revascularization —
Leape, 199966 USA 1995 57 18% no revascularization —
Hemingway, 200151 UK 1996–1997 908 34% no revascularization Death or non-fatal MI: HR ¼ 1.30 [0.80–2.08]
CABG necessary/appropriate
Kravitz, 199565 USA 1990–1991 424 41% no CABG 16.7 vs. 9.7%
25% no revascularization —
Leape, 199966 USA 1995 442 25% no revascularization —
Hemingway, 200151 UK 1996–1997 1353 26% no revascularization Death or non-fatal MI: HR ¼ 0.25 [0.17–0.35]
Revascularization necessary/appropriate
Kravitz, 199565 USA 1990–1991 671 25% 23.3% (none) vs. 9.3% (CABG) or 8.9% (PCI)
Leape, 199966 USA 1992 631 26% —
Filardo, 200164 Italy 1995 1213 29% Survival: HR ¼ 0.31 [0.19–0.51]
Epstein, 200363 USA 1991–1992 1526a and 2049b 23.9%a and 24.6%b —
HR, hazard ratio; MI, myocardial infarction; other abbreviations as previously.
aAccording to RAND method.
bAccording to ACC/AHA method.
Heart Team decision-making in CAD 2515
by guest on August 11, 2015
D
ow
nloaded from
 
where all input is acknowledged with transparent positive and
negative feedback.
The frequency and length of Heart Team meetings depend strong-
ly on the caseload and complexity of patients. Ideally, the Heart Team
should convene on a regular basis so that the length of the meetings
can be kept to a minimum and each case can be discussed in 5–
10 min. A lower number of meetings results in a higher number of
cases to be discussed and physicians can become less motivated to
actively attend lengthy meetings. For centres that do not have an
on-site surgical department, Heart Team meetings can be organized
through teleconference with the potential for integrated WebEx
screen sharing. For complex cases, surgical consultation may be
obtained through weekly meetings. Tumour boards often convene
through teleconference to discuss patients to obtain multiple
experts’ opinions about treatment strategies and discuss whether
referral to centres of excellence is warranted.
Logistics are of course the major barrier to convening the Heart
Team. In some institutions, at least initially, ad hoc meetings
between interventional cardiologist and cardiac surgeon may be
the best approach to initiate collaboration. What works well in
one institution may not be the optimal approach in another. Suc-
cessful realization of regular multidisciplinary team evaluation is
based on participation of all the necessary physicians.
Involvement
Clinical/non-invasive cardiologists, interventional cardiologists, and
cardiac surgeons should always be present to evaluate whether
optimal medical therapy, PCI, or CABG is the preferred treatment.
However, other physicians with specific expertise can be added if
necessary. An anaesthesiologist can assess surgical risk in potential
CABG patients by providing input about the ability of the patient
to safely undergo general anaesthesia. Residents and/or schooled
Figure 3 SYNTAX trial recruitment. CTO, chronic total occlusion; LM, left main; other abbreviations as previously.
Figure 4 Probability of survival according to the treatment se-
lection per randomization or clinical judgement. Before random-
ization in the MASS II trial took place, two experienced
cardiologists had to state their preference of therapy. This table
shows the survival of patients as they were treated by the rando-
mized therapy, set out against the survival that would have been
the case if the preferred treatment had been given. Copied with
permission from Pereira et al.74 Abbreviations as previously.
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research nurses should have gathered the necessary data to inter-
pret, and share the prepared score assessments on a plenary
screen so that definition, typing, or re-calculation errors can be
avoided through feedback by the rest of the team.
The concept of shared decision-making with physicians and
patients has received more emphasis, and patients should be inte-
grated in the process of decision-making (Figure 5). Involvement of
patients’ families and friends in the Heart Team can increase
patient satisfaction.77 A prospective cohort study of 3045 CABG
patients treated at 16 hospitals showed that a ‘supportive group
culture’ in hospitals was significantly correlated with higher
patient physical and mental health scores as determined by SF-36
questionnaires 6 months post-CABG.78
Decision-making should be based on three key points: (i) knowl-
edge transfer, in which it is equally important that the physician
provides information to the patient and the patient to the phys-
ician, (ii) discussion, and (iii) reaching an agreement on which
revascularization strategy will be performed in which patient pre-
ferences should be prioritized. It is crucial that during the exchange
of information at least a team of one clinical/non-invasive cardiolo-
gist, an interventional cardiologist, and a cardiac surgeon is present
to ensure that sufficient information on pros and cons of all
therapies is provided to the patient.
Additional advantages
Physicians can be held accountable for inappropriate decision-
making and can ultimately face medico-legal consequences. In
general, team physicians ‘share the burden’ and this approach
might potentially minimize medical malpractice exposure, because
there is a shared responsibility of recommending the most optimal
therapy to the patient. Nevertheless, all members of the team can
be held accountable for decisions within their expertise.79
In a group discussion, it is gratifying and self-assuring to be
acknowledged for an opinion that is shared with peers, and multi-
disciplinary approaches have been linked to improved well-being of
physicians.80
Another benefit of the Heart Team approach is creating a more
robust clinical research program with enhanced quality of care
monitoring. Studies suggest that the use of multidisciplinary
teams can increase trial recruitment.81 Information regarding exist-
ing and new therapies is more complete, and patients can interpret
the advantages and disadvantages of these treatments to decide
whether they are willing to be enrolled in a randomized trial.
Validation of the Heart Team
Although we have summarized the rationale in support of a Heart
Team approach, it is difficult to upgrade the class 1C recommen-
dation in the current guidelines.4,5 Because of the lack of rando-
mized data, it is crucial to perform observational studies to
produce data on the pros and cons of the Heart Team. Currently,
only a single study has reported that decisions made by the Heart
Team are reproducible.82
Several hypothetical designs are listed in Table 5. Although there
are limitations to such designs, these studies will provide the ne-
cessary insights into adoption of the Heart Team and determine
whether joint decision-making and treatment recommendations
can increase uniformity of care, adherence to practice guidelines,
and decrease the number of patients receiving inappropriate care.
Limitations of the Heart Team
The Heart Team approach can cause delays in decision-making and
treatment, inefficiency in care, and increased expense by foregoing
‘ad hoc’ decisions. Heart Team meetings furthermore require an in-
vestment in time of surgeons, cardiologists, and ancillary personal,
thereby increasing direct costs. One might therefore suggest that
the Heart Team should only convene specifically for those cases
in which there is a legitimate question regarding which revascular-
ization strategy should be recommended, and whether treatment
decisions can be made without a formal Heart Team meeting. Sur-
geons and (interventional) cardiologists can specify in a local
Table 5 Possible study designs to validate and evaluate the Heart Team concept
Exploring the reproducibility of the Heart Team by presenting treatment decision of specific cases to different Heart Teams. For example, this can be
done for teams in different regions or teams with different inclusion/consistencies of physicians;
Assessing the change in treatment recommendation by comparing an initial individual physician’s evaluation to a re-evaluation by the Heart Team;
Cluster randomized trial in which centres evaluate patients either in a Heart Team or according to the original referral patterns by the surgeon or
cardiologist;
Before-and-after study to compare treatment decisions and outcomes before and after implementation of a Heart Team;
Comparison of treatment decisions and outcomes of different centres with and without Heart Team evaluation.
Figure 5 The basis for a Heart Team is involvement of neces-
sary specialties and the patient to facilitate shared decision-
making. Copied with permission from Wijns et al.85 CAD ¼
coronary artery disease.
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protocol which patients can be left out from a Heart Team
meeting, e.g. patients with single vessel disease; according to the
2010 ESC/EACTS revascularization guidelines, patients with low
lesion complexity (e.g. single- or double-vessel disease) may
undergo ad-hoc stenting to avoid two separate catheterizations.4
It is recommended to schedule an informal ‘time-out’ to allow sur-
gical consultation in the catheterization laboratory; this concept
could therefore accelerate the decision-making process in relative-
ly simple cases and in patients with acute coronary syndromes.
However, ischaemia, fractional-flow reserve, or the SYNTAX
score should be recorded to allow the opportunity for active
decision-making as well as the reasons for preclusion of a formal
Heart Team discussion so that treatment decisions can retrospect-
ively be acknowledged.
Still, the increased short-term costs associated with multidiscip-
linary meetings may be of concern. However, in the Netherlands
for example, health care providers reimburse the Heart Team as
it is likely to reduce inappropriate revascularization and improve
outcomes on the long-term, which will compensate for these
investments. In some fragmented health care systems, some
payers might be concerned with increased short-term cost
without acknowledging benefit from reduced long-term costs,
and the different parties should attempt to come to an agreement
so that the Heart Team approach is beneficial for all those
involved.
In the early phase of PCI introduction, surgeons had the ability
to influence hospital decisions postponing large-scale PCI use; in
several institutions with highly influential cardiac surgeons, the
adoption rate of PCI was lower than in other institutions where
they were less influential.83 There have been concerns that multi-
disciplinary decision-making can be based on autocratic individuals
that consider themselves highest on the hierarchical tree.80 This
could result in revascularization strategies that are chosen by the
highest rank without a real team discussion. Adherence to
current clinical guidelines can then become questionable. Never-
theless, oncology studies have shown that the use of multidisciplin-
ary teams resulted in treatment that is more congruent with
evidence-based recommendations and guidelines.3,77 Although it
has been implied that improved concordance with revasculariza-
tion guidelines can be achieved by multidisciplinary input,9 this
requires further investigation.
There is evidence suggesting that the longer a team has worked
together, the more pleasant, interactive, and successful it becomes.
The initial experiences of a Heart Team might therefore not always
be positive, but it is crucial to maintain the initiative as it could
eventually lead to better treatment recommendations and person-
al wellbeing.
Conclusions
Underutilization, overutilization, and inappropriate use of myocar-
dial revascularization are common, and rates differ significantly
between geographic regions and hospitals. Clinical and anatomical
risk scores that are used for decision-making have notable inter-
and intra-observer variability and this can therefore lead to in-
accurate treatment recommendations. A balanced multidisciplinary
Heart Team, consisting of at least a clinical/non-invasive
cardiologist, interventional cardiologist, and cardiac surgeon, has
the potential to (i) better interpret the available diagnostics, (ii) im-
plement guideline directed therapy, (iii) consider local expertise,
and (iv) through shared decision-making take into account
patient preferences, to provide a more objective and uniform
decision-making process. Even though definitive data from trials
demonstrating a direct patient benefit to the Heart Team approach
is lacking, indirect evidence from both cardiac disease and oncol-
ogy fields strongly recommends the implementation of the Heart
Team.
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